πŸ‡ΊπŸ‡Έ FDA
Patent

US 9732359

Replication-competent adenoviral vectors

granted A61KA61K2039/5256A61K2039/575

Quick answer

US patent 9732359 (Replication-competent adenoviral vectors) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Aug 15 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 10 2037 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
21
CPC classes
A61K, A61K2039/5256, A61K2039/575, A61K39/21